PATENT

Customer No. 22,852

Attorney Docket No. 08201.0024-01000

O1 P.E. C34

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

MACKAY et al.

\_ \_\_.

Application No.: 10/045,574

Filed: November 7, 2001

For: BAFF, INHIBITORS THEREOF

AND THEIR USE IN THE MODULATION OF B-CELL RESPONSE AND TREATMENT

OF AUTOIMMUNE DISORDERS

Commissioner for Patents

Washington, DC 20231

Group Art Unit: 1644

Examiner: M. Haddad

RECEIVED

APR 2 8 2003

**TECH CENTER 1600/2900** 

Sir:

## INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached PTO 1449. This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

Copies of the listed documents were previously submitted in a prior application, application no. 09/911,777, filing date July 24, 2001, upon which applicant relies for the benefits provided in 35 U.S.C. § 120.

Applicants respectfully request that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form.

FINNEGAN HENDERSON FARABOW GARRETT & DUNNERLL

1300 I Street, NW Washington, DC 20005 202.408.4000 Fax 202.408.4400 www.finnegan.com

PATENT Customer No. 22,852 Attorney Docket No. 08201.0024-01000

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER, L.L.P.

Dated:

Lpril 25 2003

Leslie A. McDonell

Reg. No. 34,872

FINNEGAN HENDERSON FARABOW GARRETT & DUNNERLL

1300 I Street, NW Washington, DC 20005 202.408.4000 Fax 202.408.4400 www.finnegan.com



	TRADEM			
Atty. Docket No.	08201.0024-01000	Appln. No.	10/045,574	
Applicant	MACKAY et al.			A PA CON
Filing Date	November 7, 2001	Group:	1644	ECH CENT 28 200

U.S. PATENT DOCUMENTS				060/2900		
Examiner Initial*	Document Number	Issue/Filing Date	Name	Clas s	Sub Class	Filing Date If Appropriate
	6,475,986 B1	11/5/02	Aggarwal			
	6,475,987 B1	11/5/02	Shu			
	US 20030023038 A1	01-2003	Rennert et al.			

Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or N
WO 99/12964	3/18/99	PCT			
 WO 99/12965	3/18/99	PCT			
WO 00/40716	7/13/00	PCT			
WO 00/43032	7/27/00	PCT			, , , , , , , , , , , , , , , , , , , ,
 WO 00/50633	8/31/00	PCT			
 WO 00/68378	11/16/00	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
International Search Report, International Application No. PCT/US00/01788, mailed July 26, 2000
Colman PM, "Effects of Amino Acid Sequence Changes on Antibody-Antigen Interactions" Res. Immunol., 145:33-36 (1994)
Gras et al., "BCMAp: An Integral Membrane Protein in the Golgi Apparatus of Human Mature B Lymphocytes" Int'l Immunol., 7:1093-1106 (1995)
Gross et al., "TACI and BCMA are Receptors for a TNF Homologue Implicated in B-Cell Autoimmune Disease" <i>Nature</i> , 404:995-999 (2000)
Hahne et al., "APRIL, A New Ligand of the Tumor Necrosis Factor Family, Stimulates Tumor Cell Growth" <i>J. Exp. Med.</i> , 188:1185-1190 (1998)
Harlow et al., Antibodies A Laboratory Manual, Cold Spring Harbor, New York: ColdSpring Harbor Laboratory Press, (1988)
Khare et al., "Severe B Cell Hyperplasia and Autoimmune Disease TALL-1 Transgenic Mice" PNAS, 97:3370-3375 (2000)



Atty. Docket No.	0829499024-01000	Appln. No.	10/045,574	785			
Applicant	MACKAY et al.	. <del></del>		A APO S			
Filing Date	November 7, 2001	Group:	1644	1 APR 2 8 2003 1 CH CENTER 100/2900			
	OTHER DOCUMENTS (Including A	uthor, Title, Da	ate, Pertinent Pages	s, Etc.)			
	Kogan et al., "A Single Amino Acid R Biol. Chem., 270:14047-55 (1995)	esidue Can De	etermine the Ligand				
	Kwon et al., "Functions of Newly Ider Receptor/Ligand Superfamilies in Ly						
		Laabi et al., "A New Gene, BCM, on Chromosome 16 is Fused to the Interleukin 2 Gene by a t(4;16) (q26;p13) Translocation in a Malignant T Cell Lymphoma" <i>EMBO Journal</i> , 11;3897-3904 (1992)					
	Laabi et al., "The BCMA Gene, Preferentially Expressed During B Lymphoid Maturation, is Bidirectionally Transcribed" <i>Nucleic Acid Res.</i> , 22:1147-1154 (1994)						
	Mackay et al., "Mice Transgenic for BAFF Develop Lymphocytic Disorders Along with Autoimmune Manifestations" J. Exp. Med., 190:1697-1710 (1999)						
	Maldry et al., "The Characterization of Murine BCMA Gene Defies it as a New Memer of the Tumo Necrosis Factor Receptor Superfamily" Int'l Immunol., 10:1693-1702 (1998)						
	Mukhopadhyay et al., "Identification and Characterization of a Novel Cytokine, THANK, a TNF Homologue that Activates Apoptosis, Nuclear Factor-kappaB, and c-Jun NH2-Terminal Kinase" <i>J. Biol. Chem.</i> , 274:15978-15981 (1999)						
	Moore et al., "BlyS: Member of the Tumor Necrosis Factor Family and B Lymphocyte Stimulator" Science, 285:260-263 (1999)						
	Pitti et al., "Genomic Amplification of a Decoy Receptor for Fas Ligand in Lung and Colon Cancer" Nature, 396:699-703 (1998)						
	Schneider et al., "BAFF, a Novel Ligand of the Tumor Necrosis Factor Family, Stimulates B Cell Growth" J. Exp. Med., 189:1747-1756 (1999)						
	Shu et al., "B Cell Maturation Protein is a Receptor for the Tumor Necrosis Factor Family Member TALL-1" PNAS, 97:9156-9161 (2000)						
	Thompson et al., "BAFF Interacts with the Orphan Receptor BCMA" Scandinavian J. Immunol., 51:65 (2000)						
	Thompson et al., "BAFF Binds to the Tumor Necrosis Factor Receptor-like Molecule B Cell Maturation Antigen and is Important for Maintaining the Peripheral B Cell Population" <i>J. Exp. Med</i> 192:129-135 (2000)						
	Ward et al., "Blocking of Adhesion M Immunol., 1:165-171 (1994)	olecules In Viv	o as Anti-Inflammato	ory Therapy" <i>Ther.</i>			
	Ware CF, "APRIL and BAFF Connec	t Autoimmunity	y and Cancer" J. Exp	. Med., 192:F35-8 (2000)			
	Xia et al., "TACI is a TRAF-Interactin Member Involved in B Cell Regulatio						

OMB No. 0651-0011

ADo	Ann a s	ର		
ALL.	2 5 2003	ິດ) ANFORMATIOI	N DISCLOSUR	<b>E CITATION</b>

Atty. Docket No.	0829402000	Appln. No.	10/045,574
Applicant	MACKAY et al.		
Filing Date	November 7, 2001	Group:	1644
		1	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)
Yu et al., "APRIL and TALL-1 and Receptors BCMA and TACI: System for Regulating Humoral Immunity" <i>Nature Immunol.</i> , 1:252-256 (2000)

Examiner		Date Considered
*Examiner:	Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	
Form PTO 1449 Patent and		nt and Trademark Office - U.S. Department of Commerce

RECEIVED

APR 2 8 2003

**TECH CENTER 1600/2900**